Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO November 12, 2025
Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO October 14, 2025
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials June 9, 2025
